Objective: Increased activity of PI3K/AKT/mTOR pathway has been observed in a huge number of malignancies. This pathway can function as a prosurvival factor in leukemia stem cells and early committed leukemic precursors and its inhibition is regarded as a therapeutic approach. Accordingly, the aim of this review is to evaluate the PI3K/Akt/mTOR inhibitors used in leukemia models. Discussion: Inhibition of the PI3K/AKT/mTOR pathway has been reported to have beneficial therapeutic effects in leukemias, both in vitro in leukemia cell lines and in vivo in animal models. Overall, the use of dual PI3K/mTOR inhibitor, dual Akt/RTK inhibitor, Akt inhibitor, selective inhibitor of PI3K, mTOR inhibitor and dual PI3K/PDK1 inhibitor in CML, AML, APL, CLL, B-ALL and T-ALL has a better therapeutic effect than conventional treatments. Conclusions: Targeting the PI3K/Akt/mTOR pathway may have pro-apoptotic and antiproliferative effects on hematological malignancies. Furthermore, modulation of miRNA can be used as a novel therapeutic approach to regulate the PI3K/Akt/mTOR pathway. However, both aspects require further clinical studies.

Targeting PI3K/AKT/mTOR network for treatment of leukemia / Bertacchini, Jessika; Heidari, Nazanin; Mediani, Laura; Capitani, Silvano; Shahjahani, Mohammad; Ahmadzadeh, Ahmad; Saki, Najmaldin. - In: CELLULAR AND MOLECULAR LIFE SCIENCES. - ISSN 1420-682X. - 72:12(2015), pp. 2337-2347. [10.1007/s00018-015-1867-5]

Targeting PI3K/AKT/mTOR network for treatment of leukemia

BERTACCHINI, Jessika;MEDIANI, LAURA;
2015

Abstract

Objective: Increased activity of PI3K/AKT/mTOR pathway has been observed in a huge number of malignancies. This pathway can function as a prosurvival factor in leukemia stem cells and early committed leukemic precursors and its inhibition is regarded as a therapeutic approach. Accordingly, the aim of this review is to evaluate the PI3K/Akt/mTOR inhibitors used in leukemia models. Discussion: Inhibition of the PI3K/AKT/mTOR pathway has been reported to have beneficial therapeutic effects in leukemias, both in vitro in leukemia cell lines and in vivo in animal models. Overall, the use of dual PI3K/mTOR inhibitor, dual Akt/RTK inhibitor, Akt inhibitor, selective inhibitor of PI3K, mTOR inhibitor and dual PI3K/PDK1 inhibitor in CML, AML, APL, CLL, B-ALL and T-ALL has a better therapeutic effect than conventional treatments. Conclusions: Targeting the PI3K/Akt/mTOR pathway may have pro-apoptotic and antiproliferative effects on hematological malignancies. Furthermore, modulation of miRNA can be used as a novel therapeutic approach to regulate the PI3K/Akt/mTOR pathway. However, both aspects require further clinical studies.
2015
25-feb-2015
72
12
2337
2347
Targeting PI3K/AKT/mTOR network for treatment of leukemia / Bertacchini, Jessika; Heidari, Nazanin; Mediani, Laura; Capitani, Silvano; Shahjahani, Mohammad; Ahmadzadeh, Ahmad; Saki, Najmaldin. - In: CELLULAR AND MOLECULAR LIFE SCIENCES. - ISSN 1420-682X. - 72:12(2015), pp. 2337-2347. [10.1007/s00018-015-1867-5]
Bertacchini, Jessika; Heidari, Nazanin; Mediani, Laura; Capitani, Silvano; Shahjahani, Mohammad; Ahmadzadeh, Ahmad; Saki, Najmaldin
File in questo prodotto:
File Dimensione Formato  
bertacchini2015.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 542.26 kB
Formato Adobe PDF
542.26 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1135979
Citazioni
  • ???jsp.display-item.citation.pmc??? 109
  • Scopus 205
  • ???jsp.display-item.citation.isi??? 186
social impact